首页> 美国卫生研究院文献>Frontiers in Oncology >Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study

【2h】

Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study

机译：Lenalidomide和Rituximab方案结合玻璃体甲氨蝶呤其次是原发性培养物淋巴瘤的Lenalidomide维持：前瞻性二期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Frontiers in Oncology
作者
Yan Zhang; Xiao Zhang; Dongmei Zou; Jingjing Yin; Li Zhang; Xuan Wang; Congwei Jia; Wei Wang; Danqing Zhao; Daobin Zhou; Wei Zhang; Meifen Zhang;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：原发性培体淋巴瘤（PVRL）;RITUXIMAB;Lenalidomide;玻璃体氨基甲醇溶解注射;安全;

相似文献

外文文献
中文文献

1. Initial Results of a Phase II Study of Sequential Chemotherapy and Lenalidomide Followed By Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma [J] . Kumar Anita, Zelenetz Andrew D., Batlevi Connie Lee, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：序贯化疗和Lenalidomide的II期研究的初始结果，其次是Rituximab和Lenalidomide维持未处理的外壳细胞淋巴瘤
2. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study [J] . Egle Alexander, Steurer Michael, Melchardt Thomas, Annals of hematology . 2018,第10期

机译：氟赤胺和利妥昔单抗随后具有升高的Lenalidomide剂量，然后是先前未经处理的慢性淋巴细胞白血病（CLL）中的Lenalidomide / Rituximab维持：Revlirit CLL-5 AgMT期I / II研究
3. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study (vol 97, pg 1, 2018) [J] . Egle Alexander, Steurer Michael, Melchardt Thomas, Annals of hematology . 2018,第9期

机译：Fludarabine和Rituximab与升级的Lenalidomide剂量升级，然后在先前未经处理的慢性慢性淋巴细胞白血病（CLL）中是Lenalidomide / Rituximab维持：Revlirit CLL-5 AgMT期I / II研究（Vol 97，PG 1，2018）
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma [O] . Nishitha M. Reddy, John P. Greer, David S. Morgan, -1

机译：高/中危弥漫性大B细胞淋巴瘤患者标准化疗后来那度胺或来那度胺和利妥昔单抗作为维持治疗的II期随机研究
7. Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study [O] . Yan Zhang, Xiao Zhang, Dongmei Zou, 2021

机译：Lenalidomide和Rituximab方案结合玻璃体甲氨蝶呤，其次是原发性培养物淋巴瘤的Lenalidomide维持：前瞻性二期研究

Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study

著录项

相似文献

相关主题

期刊订阅